Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023
Friday, November 10, 2023 BiopharmaWatch Research 1 min read
Key Takeaway: Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023
Price reaction · baseline $2.8 (2023-11-09 close) · hit after-hours · 1 other SGMT headline(s) in the window, move may be shared
day 0 close
-7.7%
day 1 · peak
-20.4%
day 3
-11.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023.